Counterfeit Colgate-Palmolive toothpaste: Recalled following reports of four cases of mouth irritation, FDA reports in the Oct. 9 Enforcement Report. The product, which Colgate-Palmolive says is counterfeit, is labeled as being manufactured by Colgate-Palmolive, Bombay, India. The products were distributed in California and the U.K. Beverly Hills, Calif.-based International Marketing and Management Services initiated the Class II recall (may cause temporary or medically reversible adverse health consequences) for 743 cases (144 tubes per case) via letter Aug. 21. The recall has been completed...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.
It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.
Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.
